R. Schinazi, P. Halfon, P. Marcellin, and T. Asselah, HCV direct-acting antiviral agents: the best interferon-free combinations, Liver International, vol.15, issue.Suppl, pp.69-78, 2014.
DOI : 10.1111/liv.12423

A. Kohli, A. Shaffer, A. Sherman, and S. Kottilil, Treatment of Hepatitis C, JAMA, vol.312, issue.6, pp.631-671, 2014.
DOI : 10.1001/jama.2014.7085

E. Meissner, D. Wu, A. Osinusi, D. Bon, K. Virtaneva et al., Endogenous intrahepatic IFNs and association with IFN-free HCV treatment outcome, Journal of Clinical Investigation, vol.124, issue.8, pp.3352-63, 2014.
DOI : 10.1172/JCI75938DS1

B. Martin, N. Hennecke, V. Lohmann, A. Kayser, C. Neumann-haefelin et al., Restoration of HCV-specific CD8+ T cell function by interferon-free therapy, Journal of Hepatology, vol.61, issue.3, pp.538-581, 2014.
DOI : 10.1016/j.jhep.2014.05.043

E. Meissner, Continued value in understanding viral kinetic decline during interferon-free therapy for HCV. Liver international: official journal of the International Association for the Study of the Liver, pp.295-301, 2015.

A. Hill, G. Cooke, and . Medicine, Hepatitis C can be cured globally, but at what cost?, Science, vol.345, issue.6193, 2014.
DOI : 10.1126/science.1257737

M. Zeremski, L. Petrovic, L. Chiriboga, Q. Brown, H. Yee et al., Intrahepatic levels of CXCR3-associated chemokines correlate with liver inflammation and fibrosis in chronic hepatitis C, Hepatology, vol.194, issue.Suppl 2, p.2579317, 2008.
DOI : 10.1002/hep.22500

J. Brownell, J. Wagoner, E. Lovelace, D. Thirstrup, I. Mohar et al., Independent, parallel pathways to CXCL10 induction in HCV-infected hepatocytes, Journal of Hepatology, vol.59, issue.4, pp.701-709, 2013.
DOI : 10.1016/j.jhep.2013.06.001

J. Larrubia, M. Calvino, S. Benito, E. Sanz-de-villalobos, C. Perna et al., The role of CCR5/CXCR3 expressing CD8+ cells in liver damage and viral control during persistent hepatitis C virus infection, Journal of Hepatology, vol.47, issue.5, pp.632-673, 2007.
DOI : 10.1016/j.jhep.2007.04.009

M. Zeremski, L. Petrovic, and A. Talal, The role of chemokines as inflammatory mediators in chronic hepatitis C virus infection, Journal of Viral Hepatitis, vol.25, issue.0, pp.675-87, 2007.
DOI : 10.1016/S0168-8278(02)00429-4

M. Zeremski, G. Hooker, M. Shu, E. Winkelstein, Q. Brown et al., Induction of CXCR3- and CCR5-associated chemokines during acute hepatitis C virus infection, Journal of Hepatology, vol.55, issue.3, pp.545-53, 2011.
DOI : 10.1016/j.jhep.2010.12.033

N. Nguyen, C. De-esch, C. B. Kumar, R. Zekry, A. Lloyd et al., Positioning of leukocyte subsets in the portal and lobular compartments of hepatitis C virus-infected liver correlates with local chemokine expression, Journal of Gastroenterology and Hepatology, vol.196, issue.4, pp.860-869, 2014.
DOI : 10.1111/jgh.12462

M. Diago, G. Castellano, J. Garcia-samaniego, C. Perez, I. Fernandez et al., Association of pretreatment serum interferon ?? inducible protein 10 levels with sustained virological response to peginterferon plus ribavirin therapy in genotype 1 infected patients with chronic hepatitis C, Gut, vol.55, issue.3, pp.374-383, 2005.
DOI : 10.1136/gut.2005.074062

M. Lagging, A. Romero, J. Westin, G. Norkrans, A. Dhillon et al., IP-10 predicts viral response and therapeutic outcome in difficult-to-treat patients with HCV genotype 1 infection, Hepatology, vol.38, issue.6, pp.1617-1642, 2006.
DOI : 10.1002/hep.21407

A. Romero, M. Lagging, J. Westin, A. Dhillon, L. Dustin et al., Interferon (IFN)-gammainducible protein-10: association with histological results, viral kinetics, and outcome during treatment with pegylated IFN-alpha 2a and ribavirin for chronic hepatitis C virus infection, J Infect Dis, vol.194507307, issue.7, pp.895-903, 2006.

J. Darling, J. Aerssens, G. Fanning, J. Mchutchison, D. Goldstein et al., Quantitation of pretreatment serum interferon-??-inducible protein-10 improves the predictive value of an IL28B gene polymorphism for hepatitis C treatment response, Hepatology, vol.8, issue.1, pp.14-22, 2011.
DOI : 10.1002/hep.24056

S. Beinhardt, J. Aberle, M. Strasser, E. Dulic-lakovic, A. Maieron et al., Serum Level of IP-10 Increases Predictive Value of IL28B Polymorphisms for Spontaneous Clearance of Acute HCV Infection, Gastroenterology, vol.142, issue.1, pp.78-85, 2012.
DOI : 10.1053/j.gastro.2011.09.039

A. Casrouge, A. Bisiaux, L. Stephen, M. Schmolz, J. Mapes et al., Discrimination of agonist and antagonist forms of CXCL10 in biological samples, Clinical & Experimental Immunology, vol.110, issue.1, pp.137-185, 2012.
DOI : 10.1111/j.1365-2249.2011.04488.x

URL : https://hal.archives-ouvertes.fr/pasteur-01402047

A. Casrouge, J. Decalf, M. Ahloulay, C. Lababidi, H. Mansour et al., Evidence for an antagonist form of the chemokine CXCL10 in patients chronically infected with HCV, Journal of Clinical Investigation, vol.121, issue.1, pp.308-325, 2011.
DOI : 10.1172/JCI40594DS1

URL : https://hal.archives-ouvertes.fr/pasteur-01402089

A. Riva, M. Laird, A. Casrouge, A. Ambrozaitis, R. Williams et al., Truncated CXCL10 is associated with failure to achieve spontaneous clearance of acute hepatitis C infection, Hepatology, vol.22, issue.2, pp.487-96, 2014.
DOI : 10.1002/hep.27139

URL : https://hal.archives-ouvertes.fr/pasteur-01384520

D. Ragab, M. Laird, D. Duffy, A. Casrouge, R. Mamdouh et al., CXCL10 antagonism and plasma sDPPIV correlate with increasing liver disease in chronic HCV genotype 4 infected patients, Cytokine, vol.63, issue.2, pp.105-117, 2013.
DOI : 10.1016/j.cyto.2013.04.016

URL : https://hal.archives-ouvertes.fr/pasteur-01385516

J. Soderholm, J. Waldenstrom, G. Askarieh, M. Pilli, P. Bochud et al., Impact of Soluble CD26 on Treatment Outcome and Hepatitis C Virus-Specific T Cells in Chronic Hepatitis C Virus Genotype 1 Infection, PLoS ONE, vol.22, issue.2, p.3577643, 2013.
DOI : 10.1371/journal.pone.0056991.t007

D. Rissin, C. Kan, T. Campbell, S. Howes, D. Fournier et al., Single-molecule enzyme-linked immunosorbent assay detects serum proteins at subfemtomolar concentrations, Nature Biotechnology, vol.8, issue.6, pp.595-604, 2010.
DOI : 10.1038/nbt.1641

A. Osinusi, E. Meissner, Y. Lee, D. Bon, L. Heytens et al., Sofosbuvir and Ribavirin for Hepatitis C Genotype 1 in Patients With Unfavorable Treatment Characteristics, JAMA, vol.310, issue.8
DOI : 10.1001/jama.2013.109309

A. Osinusi, A. Kohli, M. Marti, A. Nelson, X. Zhang et al., Re-treatment of Chronic Hepatitis C Virus Genotype 1 Infection After Relapse, Annals of Internal Medicine, vol.161, issue.9, pp.634-642, 2014.
DOI : 10.7326/M14-1211